Trial Profile
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs IMF 001 (Primary) ; MIS 416 (Primary)
- Indications Prostate cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- 05 Jun 2018 Results (n=26) assessing safety, tolerabilty and immune response ( UMIN000008007 and UMIN000005246) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
- 14 Mar 2016 Status changed from active, no longer recruiting to completed.